Clinical Trial Update: Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial from Tanta University is evaluating whether dapagliflozin can prevent doxorubicin-induced cardiotoxicity in breast cancer patients; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Doxorubicin-induced Cardiomyopathy

Drugs mentioned

• FARXIGA (dapagliflozin)

Snippet

Sponsor: Tanta University | Conditions: Doxorubicin Induced Cardiomyopathy, Breast Cancer | Phase 2 | Status: RECRUITING